Literature DB >> 31713660

[Mass spectrometry-applications in pathology].

K Schwamborn1.   

Abstract

BACKGROUND: Currently, more complex and extensive diagnostic pathology work-up of sometimes only limited sample material is necessary to ensure optimal patient treatment. This often includes genomic analyses. However, dynamic changes within an organism or tumor can be better reflected at the protein level. Therefore, proteomic technologies would seem to be the solution.
OBJECTIVES: To evaluate the application of different proteomic techniques to analyze body fluids and tissue samples with regards to implementation in diagnostics.
MATERIALS AND METHODS: All studies utilized mass spectrometry-based methods in order to achieve differentiation of a number of different patient groups in various diseases.
RESULTS: Whereas classical proteomic methods are particularly suitable for analyzing serum samples in order to diagnose bladder cancer or chronic hepatitis C, tissue analyses would require prior tissue lyses, thus erasing possible information to be obtained from histology. Imaging mass spectrometry offers a solution as it allows for the analysis of an intact tissue section. Possible applications and the added benefit of this method could be shown using various examples of tumors (prostate cancer, Hodgkin's lymphoma, cervical cancer, and different types of adenocarcinomas).
CONCLUSIONS: Mass spectrometry-based technologies allow diagnostic confirmation with high sensitivity and specificity. In comparison to routine diagnostic approaches, results can be achieved faster, using less sample material, and with comparable accuracy.

Entities:  

Keywords:  Hodgkin disease; Mass spectrometry imaging; Matrix-assisted laser desorption-ionization mass spectrometry; Prostate cancer; Proteomics

Mesh:

Year:  2019        PMID: 31713660     DOI: 10.1007/s00292-019-00692-9

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  45 in total

Review 1.  Disease proteomics.

Authors:  Sam Hanash
Journal:  Nature       Date:  2003-03-13       Impact factor: 49.962

Review 2.  Needle in a haystack: microdissecting the proteome of a tissue.

Authors:  H J Ball; N H Hunt
Journal:  Amino Acids       Date:  2004-07-14       Impact factor: 3.520

Review 3.  Tissue and serum proteomic profiling for diagnostic and prognostic bladder cancer biomarkers.

Authors:  Kristina Schwamborn; Nadine T Gaisa; Corinna Henkel
Journal:  Expert Rev Proteomics       Date:  2010-12       Impact factor: 3.940

Review 4.  Combining laser capture microdissection and proteomics techniques.

Authors:  Dana Mustafa; Johan M Kros; Theo Luider
Journal:  Methods Mol Biol       Date:  2008

Review 5.  MALDI imaging mass spectrometry - From bench to bedside.

Authors:  Kristina Schwamborn; Mark Kriegsmann; Wilko Weichert
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2016-10-31       Impact factor: 3.036

Review 6.  Mass spectrometry and proteomics in hematology.

Authors:  Delphine C M Rolland; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  Semin Hematol       Date:  2018-05-29       Impact factor: 3.851

Review 7.  MALDI imaging mass spectrometry--painting molecular pictures.

Authors:  Kristina Schwamborn; Richard M Caprioli
Journal:  Mol Oncol       Date:  2010-09-25       Impact factor: 6.603

8.  Identification of the primary site of metastatic adenocarcinoma in serous effusions. Value of an immunocytochemical panel added to the clinical arsenal.

Authors:  Adhemar Longatto Filho; Venâncio Avancini Ferreira Alves; Cristina Takami Kanamura; Suely Nonogaki; Jeni Bortolan; Valeria Lombardo; Helio Bisi
Journal:  Acta Cytol       Date:  2002 Jul-Aug       Impact factor: 2.319

9.  Identifying prostate carcinoma by MALDI-Imaging.

Authors:  Kristina Schwamborn; René C Krieg; Marcus Reska; Gerhard Jakse; Ruth Knuechel; Axel Wellmann
Journal:  Int J Mol Med       Date:  2007-08       Impact factor: 4.101

Review 10.  Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality.

Authors:  O A Gressner; R Weiskirchen; A M Gressner
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.